Renaissance Technologies
INO icon

Renaissance Technologies’s Inovio Pharmaceuticals INO Stock Holding History

Renaissance Technologies’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$397K Sell
361,339
-282,438
-44% -$335K ﹤0.01% 2691
2026
Q1 		$1.12M Buy
643,777
+90,613
+16% +$149K ﹤0.01% 2212
2025
Q4 		$963K Sell
553,164
-263,175
-32% -$580K ﹤0.01% 2304
2025
Q3 		$1.91M Buy
816,339
+488,210
+149% +$935K ﹤0.01% 2111
2025
Q2 		$668K Buy
328,129
+282,301
+616% +$541K ﹤0.01% 2692
2025
Q1 		$74.7K Sell
45,828
-196,477
-81% -$394K ﹤0.01% 3234
2024
Q4 		$443K Sell
242,305
-88,761
-27% -$393K ﹤0.01% 2898
2024
Q3 		$1.91M Sell
331,066
-79,500
-19% -$656K ﹤0.01% 2052
2024
Q2 		$3.32M Sell
410,566
-39,700
-9% -$418K 0.01% 1562
2024
Q1 		$6.25M Sell
450,266
-157,849
-26% -$1.36M 0.01% 1269
2023
Q4 		$3.72M Buy
608,115
+200,657
+49% +$990K 0.01% 1542
2023
Q3 		$1.9M Sell
407,458
-45,565
-10% -$252K ﹤0.01% 1898
2023
Q2 		$2.43M Buy
453,023
+232,998
+106% +$1.88M ﹤0.01% 1864
2023
Q1 		$2.17M Buy
220,025
+5,650
+3% +$96.3K ﹤0.01% 1983
2022
Q4 		$4.01M Buy
214,375
+20,733
+11% +$470K 0.01% 1650
2022
Q3 		$4.01M Buy
193,642
+62,184
+47% +$1.59M 0.01% 1575
2022
Q2 		$2.73M Buy
131,458
+98,635
+301% +$2.78M ﹤0.01% 1970
2022
Q1 		$1.41M Buy
+32,823
New +$1.48M ﹤0.01% 2486
2020
Q2 		– Sell
-50,260
Closed -$4.49M – 3591
2020
Q1 		$4.49M Buy
50,260
+20,302
+68% +$1.25M ﹤0.01% 1632
2019
Q4 		$1.19M Buy
29,958
+18,716
+166% +$563K ﹤0.01% 2551
2019
Q3 		$277K Sell
11,242
-6,648
-37% -$202K ﹤0.01% 3059
2019
Q2 		$631K Sell
17,890
-29,133
-62% -$1.16M ﹤0.01% 2905
2019
Q1 		$2.1M Buy
47,023
+19,083
+68% +$962K ﹤0.01% 2284
2018
Q4 		$1.34M Sell
27,940
-3,342
-11% -$203K ﹤0.01% 2440
2018
Q3 		$2.09M Buy
31,282
+5,309
+20% +$296K ﹤0.01% 2249
2018
Q2 		$1.22M Sell
25,973
-3,175
-11% -$175K ﹤0.01% 2517
2018
Q1 		$1.65M Sell
29,148
-1,184
-4% -$64.1K ﹤0.01% 2434
2017
Q4 		$1.5M Buy
+30,332
New +$1.88M ﹤0.01% 2489
2016
Q1 		– Sell
-32,732
Closed -$2.64M – 3436
2015
Q4 		$2.64M Buy
+32,732
New +$2.61M 0.01% 1931

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Renaissance Technologies's INO Position: Q2 2026 in Review

Renaissance Technologies reduced its Inovio Pharmaceuticals (INO) stake by 44% in Q2 2026, selling an estimated $335K and leaving 361,339 shares worth $397K. The position accounts for ﹤0.01% of the portfolio, ranked #2691.

Renaissance Technologies first reported a position in INO in Q4 2015 and has held it in 29 quarters since. The position peaked at $6.25M in Q1 2024. 103 funds tracked by Wall St. Rank hold INO as of Q2 2026.

  • Renaissance Technologies held 361,339 shares of Inovio Pharmaceuticals worth $397K as of Q2 2026.
  • Renaissance Technologies sold 282,438 Inovio Pharmaceuticals shares in Q2 2026, an estimated $335K.
  • Inovio Pharmaceuticals made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2691 holding.
  • Renaissance Technologies first reported a position in Inovio Pharmaceuticals in Q4 2015 and has held it in 29 quarters since.
  • Renaissance Technologies's Inovio Pharmaceuticals position peaked at $6.25M in Q1 2024.
  • 103 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.